Company intelligence / Profile preview

Biotia

New York, New York, United States

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Biotia’s BIOTIA-ID Urine is a clinically validated, next-generation sequencing and AI-driven diagnostic with 97% sensitivity and 99% specificity for pathogen identification in UTIs. Clinical studies showed it detected pathogens missed by culture in 63% of urine samples, improving clinical management in high-risk and complicated cases[1][7].

Therapeutic areas: Infectious Diseases
Modalities: Genomics-based diagnosticNext-generation sequencing platformArtificial intelligence diagnostic software
Industry: Molecular Diagnostics

Partnerships

Boryung Corporation (South Korea)SUNY Downstate Health Sciences UniversityDr. Charles Chiu, UCSFThe Rockefeller FoundationMayo Clinic PlatformWeill Cornell MedicineMetasubFiocruz

Beyond the preview

Go deeper on Biotia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotia.

Explore the full profile